Varespladib Sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530254

CAS#: 172733-42-5

Description: Varespladib Sodium is a Secretory Phospholipase A2 Inhibitor.


Price and Availability

Size
Price

Size
Price

Size
Price

Varespladib Sodium is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 530254
Name: Varespladib Sodium
CAS#: 172733-42-5
Chemical Formula: C21H19N2NaO5
Exact Mass: 402.1192
Molecular Weight: 402.3818
Elemental Analysis: C, 62.68; H, 4.76; N, 6.96; Na, 5.71; O, 19.88


Synonym: Varespladib Sodium

IUPAC/Chemical Name: Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)-, monosodium salt

InChi Key: XZZUHXILQXLTGV-UHFFFAOYSA-M

InChi Code: InChI=1S/C21H20N2O5.Na/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13;/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25);/q;+1/p-1

SMILES Code: O=C([O-])COC1=CC=CC2=C1C(C(C(N)=O)=O)=C(CC)N2CC3=CC=CC=C3.[Na+]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Sep;31(7):463-93. PubMed PMID: 19907722.

2: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408. PubMed PMID: 18806898.

3: Tomita Y, Kuwabara K, Furue S, Tanaka K, Yamada K, Ueno M, Ono T, Maruyama T, Ajiki T, Onoyama H, Yamamoto M, Hori Y. Effect of a selective inhibitor of secretory phospholipase A2, S-5920/LY315920Na, on experimental acute pancreatitis in rats. J Pharmacol Sci. 2004 Oct;96(2):144-54. Epub 2004 Oct 2. PubMed PMID: 15467263.

4: Koike K, Yamamoto Y, Hori Y, Ono T. Group IIA phospholipase A2 mediates lung injury in intestinal ischemia-reperfusion. Ann Surg. 2000 Jul;232(1):90-7. PubMed PMID: 10862200; PubMed Central PMCID: PMC1421112.